SEC Form 4 · accession 0001179110-18-012085
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
Oct 5, 2018
Accepted (ET)
Oct 9, 2018 · 2:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 7, 2018 | G | 294 | $0.00 | D | 325,745 | D | |
| Common StockF1 | Oct 5, 2018 | S | 5,928 | $15.5597 | D | 319,817 | D | |
| Common Stock | holding | — | — | — | 184,985 | I | By spouse trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 5,928 shares in multiple transactions ranging in price from $15.1400 to $15.9200, resulting in a weighted-average price of $15.5597. The 5,928 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.